Illustrative image – not actual.Cipla and Bengaluru-based biopharmaceutical Contract Development and Manufacturing Organisation (CDMO) Kemwell Biopharma, entered into a joint venture (JV) agreement to develop, manufacture and commercialise biosimilars for global markets.
For this purpose, a JV company will be set up with an aim to enter the respiratory biosimilars space.
Under the terms of the agreement, the JV will leverage Cipla and Kemwell’s complementary strengths for end-to-end product development, clinical development, regulatory filings, manufacturing and commercialisation of bio-pharmceutical products.
Cipla’s respiratory prowess combined with Kemwell’s expertise in biologics will accelerate bringing these essential products to the market.
For this purpose, a JV company will be set up with an aim to enter the respiratory biosimilars space.
Under the terms of the agreement, the JV will leverage Cipla and Kemwell’s complementary strengths for end-to-end product development, clinical development, regulatory filings, manufacturing and commercialisation of bio-pharmceutical products.
Cipla’s respiratory prowess combined with Kemwell’s expertise in biologics will accelerate bringing these essential products to the market.
